Io Therapeutics
Business Services · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9450 Pinecroft Dr Unit 9497, Spring, Tex...Website
www.io-therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About Io Therapeutics
Io Therapeutics, Inc. is a privately held biopharmaceutical company based in Houston, Texas, focused on discovering and developing therapeutic compounds that target nuclear receptors for the treatment of cancer, neurodegenerative, and autoimmune diseases. The company specializes in small molecule drugs, particularly retinoids and rexinoids, which interact with nuclear receptors to control gene expression. Their research has significantly advanced the understanding of cancer biology, neurodegenerative diseases like Alzheimer's and Parkinson's, and autoimmune disease mechanisms. Io Therapeutics aims to provide innovative solutions for patients suffering from these complex conditions.Explore more
Io Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Io Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Io Therapeutics launches new products
Click to see if Io Therapeutics had a recent Job posting/layoffs
Check out if Io Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Io Therapeutics
Io Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Io Therapeutics has new funding data
Earning: See what the market has to say on Io Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Io Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Io Therapeutics
Find 2 more new buyers
Compare Similar Companies to Io Therapeutics
Compare insights from companies similar to Io Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Io Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Io Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Io Therapeutics.
Io Therapeutics financials insights
Gather financial insights about Io Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$20K
Io Therapeutics Tech Stack
A closer look at the technologies used by Io Therapeutics
See more technologies
Io Therapeutics News & Media
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
Io Therapeutics reports publication of studies on its RXR agonist compound for prevention of Triple Negative Breast Cancer.Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).
Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cellsIo Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
Io Therapeutics announced at the American Society of Hematology studies of their RXR agonist IRX4204 in combination with CAR-T cells for multiple myelomaScientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
Scientists at Dalhousie University and Io Therapeutics publish data on effectiveness of IRX4204 in reversing demyelination in a model of multiple sclerosis
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Io Therapeutics
Sign Up For FreeTo access detailed company insights
Io Therapeutics, Inc. is a privately held biopharmaceutical company based in Houston, Texas, focused on discovering and developing therapeutic compounds that target nuclear receptors for the treatment of cancer, neurodegenerative, and autoimmune diseases. The company specializes in small molecule drugs, particularly retinoids and rexinoids, which i... Read More
